{
    "clinical_study": {
        "@rank": "61962", 
        "arm_group": [
            {
                "arm_group_label": "Atorvastatin 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Atorvastatin 20mg daily for 1 year"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo daily for 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "Biochemical recurrence develops in approximately 30-40% of men with locally advanced\n      prostate cancer who undergo radical prostatectomy. To date, the effect of statins on\n      prostate cancer recurrence has been investigated in several retrospective studies with\n      inconsistent results. The purpose of this study is to determine the impact of statin on\n      biochemical recurrence after radical prostatectomy for locally advanced prostate cancer."
        }, 
        "brief_title": "Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Estimated Enrollment: 354\n\n      Study start date: October 2012\n\n      Estimated Study Completion Date: October 2015\n\n      Statin Group: Treatment with Atorvastatin 20mg daily after radical prostatectomy during 1\n      year.\n\n      Control Group: Treatment with Placebo daily after radical prostatectomy during 1 year.\n\n      Follow up: every 3 months for the first year. Check PSA, Total/LDL-cholesterol and\n      Triglyceride.\n\n      Primary End Point Rate of Biochemical recurrence\n\n      Secondary End Point Clinical progression of prostate cancer Change of Total/LDL- cholesterol\n      and Triglycerides 5 year-Biochemical recurrence free survival"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients must have correspond to one of the following three pathologic criteria.\n\n             A. Gleason scores 8 or greater B. Positive resection margin C. pT3-T4\n\n          2. Patients must have pathologically adenocarcinoma\n\n          3. Patients must be enrolled within 60 days after radical prostatectomy\n\n          4. Patients must be able to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. Patients who have received neoadjuvant androgen deprivation therapy\n\n          2. Patients who have the participation of other clinical trial within the past 3 months\n\n          3. Patients who have treated with statin\n\n          4. Patients who have lymph node metastasis or distant metastasis\n\n          5. Patients who have 10 year risk of cardiovascular disease over 10% based on NCEP ATP\n             III guideline."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "354", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759836", 
            "org_study_id": "AMC-PC2012002"
        }, 
        "intervention": {
            "arm_group_label": "Atorvastatin 20mg", 
            "description": "Atorvastatin 20mg daily for 1 year", 
            "intervention_name": "Atorvastatin 20mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostatectomy", 
            "Statins"
        ], 
        "lastchanged_date": "January 9, 2013", 
        "location": {
            "contact": {
                "email": "cskim@amc.seoul.kr", 
                "last_name": "Choung-Soo Kim, MD", 
                "phone": "82-2-3010-3734", 
                "phone_ext": "No"
            }, 
            "contact_backup": {
                "email": "igjeong@amc.seoul.kr", 
                "last_name": "In Gab Jeong, MD", 
                "phone": "82-2-3010-5892", 
                "phone_ext": "No"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Choung-soo Kim, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double Blind, Placebo-controlled Study Determining the Role of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer", 
        "other_outcome": {
            "measure": "Clinical progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Five years"
        }, 
        "overall_contact": {
            "email": "cskim@amc.seoul.kr", 
            "last_name": "Choung-Soo Kim, MD", 
            "phone": "82-2-3010-3734", 
            "phone_ext": "No"
        }, 
        "overall_contact_backup": {
            "email": "igjeong@amc.seoul.kr", 
            "last_name": "In Gab Jeong, MD", 
            "phone": "82-2-3010-5892", 
            "phone_ext": "No"
        }, 
        "overall_official": {
            "affiliation": "Department of Urology,Asan Medical Center, Seoul", 
            "last_name": "Choung-Soo Kim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of biochemical recurrence", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759836"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Choung-Soo Kim", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Biochemical recurrence free survival", 
            "safety_issue": "No", 
            "time_frame": "Five years"
        }, 
        "source": "Asan Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Dong-A Pharmaceuticals. Inc", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}